Non-specialty pipeline forecast as of February 2009

[chantell.reagan]

The following list represents non-specialty pipeline updates for February 2009 from DrugPipelineForecast. In order to see these updates, you must be a registered user of DrugManagementForum (click here to register)

anacetrapib - positive Phase III data

bilastine - positive Phase III data

Effient - recommended for approval in US and approved in EU

Embeda - review extended by FDA

fluoxetine (NPL-2008) - negative Phase III data (new DrugPipelineForecast entry)

ketorolac - NDA accepted by FDA (new DrugPipelineForecast entry)

liraglutide - positive Phase III data

maribavir - negative Phase III data (new DrugPipelineForecast entry)

Multaq - positive Phase III data

paliperidone - follow-up to FDA's Complete Response letter

Pennsaid - NDA resubmission

prulifloxacin - positive Phase III data

safinamide - positive Phase III data (new DrugPipelineForecast entry)

Saphris - follow-up submission to FDA's Complete Response letter

Sumavel DosePro - review extended by FDA

toremifene - continuation of Phase III trial

Valdoxan - received marketing authorization in EU, with NDA submission planned (new DrugPipelineForecast entry)

Viviant - recommended for approval in EU

For more information, or to search additional drugs, please see DrugPipelineForecast